Aadi Bioscience, Inc. announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. Ms. Graham brings more than 20 years of biotech and pharma-specific investor relations and corporate communications experience, leading these functional areas at companies in all stages of development. She joins Aadi after most recently serving as the Vice President of Corporate Affairs at Poseida Therapeutics and previously as Vice President IR and Corporate Communications at Mirati Therapeutics.

Ms. Graham has also led investor relations and corporate communications for Ambit Biosciences prior to its eventual acquisition by Daiichi Sankyo in 2014 as well as Sequenom and Genoptix, the latter of which was acquired by Novartis in 2011.Ms. Graham earned an MBA from the University of New Mexico, Anderson School of Management and a BA in journalism, most recently completing the Strategic Financial Leadership Program at Stanford Graduate School of Business.